Literature DB >> 29188805

Prevention: Rivaroxaban plus aspirin in CAD or PAD.

Gregory B Lim.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29188805     DOI: 10.1038/nrcardio.2017.192

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Authors:  Stuart J Connolly; John W Eikelboom; Jackie Bosch; Gilles Dagenais; Leanne Dyal; Fernando Lanas; Kaj Metsarinne; Martin O'Donnell; Anthony L Dans; Jong-Won Ha; Alexandr N Parkhomenko; Alvaro A Avezum; Eva Lonn; Liu Lisheng; Christian Torp-Pedersen; Petr Widimsky; Aldo P Maggioni; Camilo Felix; Katalin Keltai; Masatsugu Hori; Khalid Yusoff; Tomasz J Guzik; Deepak L Bhatt; Kelley R H Branch; Nancy Cook Bruns; Scott D Berkowitz; Sonia S Anand; John D Varigos; Keith A A Fox; Salim Yusuf
Journal:  Lancet       Date:  2017-11-10       Impact factor: 79.321

2.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.

Authors:  Sonia S Anand; Jackie Bosch; John W Eikelboom; Stuart J Connolly; Rafael Diaz; Peter Widimsky; Victor Aboyans; Marco Alings; Ajay K Kakkar; Katalin Keltai; Aldo P Maggioni; Basil S Lewis; Stefan Störk; Jun Zhu; Patricio Lopez-Jaramillo; Martin O'Donnell; Patrick J Commerford; Dragos Vinereanu; Nana Pogosova; Lars Ryden; Keith A A Fox; Deepak L Bhatt; Frank Misselwitz; John D Varigos; Thomas Vanassche; Alvaro A Avezum; Edmond Chen; Kelley Branch; Darryl P Leong; Shrikant I Bangdiwala; Robert G Hart; Salim Yusuf
Journal:  Lancet       Date:  2017-11-10       Impact factor: 79.321

  2 in total
  1 in total

Review 1.  Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.